Evidence map›Paper›PMID 42875558›Full record

ArticleNature medicine2026

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

MacLean C Sellars, Jessica A Frank, Bohoon Shim, Allison Vanasse, Ruolin Liu, Cleo Forman, Chloe R Tu, Kyohei K Tabata, Antonia Kowelewski, Su-Chun Cheng and 32 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04024878 (NeoVax With Nivolumab in Patients With Ovarian Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04024878 phase1active not recruitingnot on this map

NeoVax With Nivolumab in Patients With Ovarian Cancer

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2020 to 2029Enrolled22ConditionsOvarian CancerArmsNivolumab, NeoVax, Core Needle Biopsy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

MacLean C SellarsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3078-4155
Jessica A FrankDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5334-3240
Bohoon ShimDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Allison VanasseTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Ruolin LiuBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9059-6335
Cleo FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chloe R TuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kyohei K TabataDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Antonia KowelewskiHarvard Medical School, Boston, MA, USA.
Su-Chun ChengDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Catherine SongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kan XiongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Pia JainBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0009-0005-7726-9352
Andjela CrnjacBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0009-0005-9651-4288
Haley E SaxDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0000-9277-086X
Vipheaviny CheaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Wesley LuTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
J Thomas JanesTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0007-0887-8482
Micah Rickles-YoungBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Amit SudDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6133-0164
Savni SarolkarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Martin HayesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Oriol OliveDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Haley GreensladeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Carrie CibulskisBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Nir HacohenHarvard Medical School, Boston, MA, USA.
Edward F FritschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8412-5665
Shuqiang LiTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9106-6141
Kenneth J LivakTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9105-5856
Nabihah TayobDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6088-167X
Elizabeth H StoverDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6578-3216
Carolyn KrasnerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rebecca PorterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ursula MatulonisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7435-5603
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4253-943X
Jeremy M SimonDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3906-1663
Viktor A AdalsteinssonBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4555-2485
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8496-6181
Panagiotis A Konstantinopoulos *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Panogiotis_Konstantinopoulos@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-1032-1479
Catherine J Wu *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Catherine_Wu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3348-5054

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4M
The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damageK08CA237871 · NCI · DANA-FARBER CANCER INST · PI STOVER, ELIZABETH HARMON · 2019 to 2023
$921k
U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA279391U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA285308U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL157174U.S. Department of Health & Human Services | National Institutes of Health (NIH) R50CA251956U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32CA009172U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54-CA272688U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08CA237871U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) NCI-1R01CA229261Wellcome Trust (Wellcome) 227000/Z/23/Z
6 · The paper itself

Abstract

Personalized neoantigen-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies. Here we report the results of a phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy. Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity. Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy. Biomarker analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination. Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination. Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. ClinicalTrials.gov identifier: NCT04024878 .

Identifiers

PMID42875558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.